<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131546</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-77</org_study_id>
    <nct_id>NCT01131546</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension</brief_title>
  <official_title>A Randomized, Controlled, Multicenter Trial of Levamlodipine Besylate Versus Amlodipine Maleate in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or
      5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who reach overall blood pressure control (defined as BP &lt;140/90 mmHg for non-diabetic patients and &lt; 130/80 mmHg for diabetic patients)</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure (SBP)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic blood pressure (DBP)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Levamlodipine besylate (2.5mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Levamlodipine besylate (5mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine maleate (5mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levamlodipine besylate</intervention_name>
    <description>Once daily, 7AM - 10AM</description>
    <arm_group_label>Levamlodipine besylate (2.5mg)</arm_group_label>
    <arm_group_label>Levamlodipine besylate (5mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine maleate</intervention_name>
    <description>Once daily, 7AM - 10AM</description>
    <arm_group_label>Amlodipine maleate (5mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients, 18-75 Years

          -  Patients with mild to moderate essential hypertension (defined as mean BP of 2 visits
             â‰¥140mm/90mmHg, and &lt; 180mm/110mmHg)

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with secondary hypertension

          -  Patients with severe hypertension

          -  Have to take other drugs that can influence blood pressure during the study

          -  Allergic to DHP calcium antagonists

          -  Evidence of congestive heart failure, unstable angina or severe arrhythmia

          -  Renal or hepatic dysfunction

          -  Women who are taking contraceptive pills or are likely to be pregnant

          -  Participate in other clinical trials within 3 months prior to this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dayi Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinming Yu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Public Health, Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 30, 2011</last_update_submitted>
  <last_update_submitted_qc>May 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jinsheng Ren</name_title>
    <organization>Jiangsu Simcere Pharmaceutical R&amp;D Co. Ltd.</organization>
  </responsible_party>
  <keyword>Essential Hypertension</keyword>
  <keyword>Levamlodipine Besylate</keyword>
  <keyword>Amlodipine Maleate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

